Aetna considers percutaneous embolization (by means of balloon or metallic coil) medically necessary for the treatment of varicocele for any of the following conditions:
Aetna considers percutaneous embolization of varicoceles for persons who do not meet these criteria experimental and investigational.
Aetna considers microsurgical varicocelectomy an acceptable alternative method of treating a varicocele when any of the afore-mentioned criteria is met.
Aetna considers endoluminal occlusion devices (e.g., the ArtVentive endoluminal occlusion system) experimental and investigational for the treatment of varicoceles because their effectiveness has not been established.Background
Varicoceles (dilations of the pampiniform venous plexus) are found in 10 to 15 % of the male population and they occur predominantly on the left side. The etiology may be a longer left spermatic vein with its right-angle insertion into the left renal vein and/or absence of valves, which results in a higher hydrostatic pressure in the left spermatic vein causing dilatation. Also, the left renal vein may be compressed between the superior mesenteric artery and the aorta. This “nutcracker phenomenon” may result in elevated pressure in the left testicular venous system. Moreover, the incidence of varicocele in men with impaired fertility is about 30 %; varicoceles are the most common surgically correctable cause of male infertility. A clinical grading system classifies varicoceles into 3 grades: (i) grade 1 (small) -- palpable only during a Valsalva maneuver, (ii) grade 2 (moderate) -- palpable without the need of the Valsalva maneuver, and (iii) grade 3 (large) -- visible.
Although varicoceles can be diagnosed by a thorough physical examination, ultrasonography is the most practical and accurate non-invasive method in diagnosing this condition. Surgical ligation (varicocelectomy) is the conventional approach in managing varicoceles. However, percutaneous embolization by means of balloon or metallic coil has been shown to be a safe and effective alternative to ligation in treating varicoceles. Embolization (of spermatic veins) of varicoceles in males with semen abnormalities has been demonstrated to improve sperm count and motility in up to 75 % of patients, and reported pregnancy rates after ablation of varicoceles vary from 30 to 60 %. Furthermore, embolization therapy has been reported to increase testicular size in adolescents with testicular hypotrophy.
Polito and colleagues (2004) stated that the impact of varicocele on male infertility is still controversial since its role on the impairment of semen quality has never been fully demonstrated. These researchers studied a series of young adult males (n = 426) undergoing percutaneous treatment of varicocele and semen parameters were evaluated at baseline and 12 months of follow-up. They concluded that the correction of varicocele in young adults is not a major indication when semen alteration is the only clinical problem. This is in agreement with the findings of Nabi et al (2004) who compared the semen quality in men with or without pregnancy after percutaneous embolization of varicoceles in the management of infertility (n = 102). They concluded that varicocele embolization is a technically feasible, minimally invasive, outpatient procedure that improves semen quality significantly in patients with a pre-embolization semen density of 10 to 30 million/ml. However, no correlation was found between the improvements in semen quality and the pregnancy rate.
Bechara et al (2009) compared the treatment outcome of percutaneous embolization treatment versus laparoscopic varicocelectomy in patients with symptomatic varicoceles. Patients with varicoceles undergoing either laparoscopic varicocelectomy or percutaneous coil embolization of the testicular vein during a recent 5-year period were analyzed. Treatment outcome and hospital costs of these two minimally invasive treatment modalities were compared. A total of 41 patients underwent percutaneous coil embolization of the testicular vein, which were compared with a cohort of 43 patients who underwent laparoscopic varicocelectomy. Technical success in interventional and laparoscopic treatment was 95 % and 100 %, respectively. The mean operative time or procedural time was 63 +/- 13 mins and 52 +/- 25 mins for interventional and laparoscopic cohorts (not significant), respectively. Embolization treatment resulted in 2 recurrent varicoceles (4.8 %) compared to 1 patient following laparoscopic repair (2.3 %, not significant). Embolization treatment was associated with a lower complication rate than laparoscopic repair (9.7 % versus 16.3 %, p = 0.03). Regarding cost analysis, no significant difference in hospital cost was noted between the interventional or laparoscopic treatment strategies. Both laparoscopic varicocelectomy and coil embolization are effective treatment modalities for varicoceles. With lower treatment complication rates in the interventional treatment group, coil embolization of the testicular vein offers treatment advantage compared with laparoscopic repair in patients with varicoceles.
Ayechu-Diaz et al (2009) stated that there are still doubts as to the most suitable criteria when considering surgery as the indication and optimal treatment for adolescent varicocele. These investigators reviewed the hospital and primary health care histories of patients diagnosed by ultrasound for varicocele over the last 7 years. Data were taken from computerized clinical histories and hard copy back-up material stored and processed in computer format. They studied 135 cases (mean age of 12.8 years). A total of 125 were referred for scrotal swelling or as a result of chance detection, except for 10 patients who reported pain or scrotal asymmetry; 73 underwent surgery and 62 continued as controls over the study period. The surgical indication was significant progressive asymmetry in testicular volume (n = 28), high grade varicocele (n = 41) as well as other reasons (n = 4). These researchers undertook percutaneous embolization in 44 patients (with a 66 % relapse rate) and laparoscopic section of the spermatic cord with no arterial preservation in 29 (no relapses but 7 post-surgery hydroceles). No testicles were lost. At the end of the study 10 children continued as controls, 34 were discharged after recovery, 56 were referred to urology due to their age group, and 35 were lost to the study. The authors concluded that in the controversy over the treatment of varicocele, their experience showed a high degree of relapses after embolization. Section of the spermatic vessels (including the artery) with no lymphatic preservation is highly effective but involves 27 % post-surgical hydroceles, usually self-limiting (only 1 patient had to undergo surgery later), with no testicular atrophy or other complications. These investigators prefer complete laparoscopic section of the spermatic pedicle to embolization; but it would be advisable to introduce modifications to avoid post-surgical hydrocele. Embolization must be reserved for patients with 1 testicle or with bilateral disease.
Storm and colleagues (2010) noted that post-operative hydrocele development is a frustrating complication of varicocele surgical repair. To avoid this complication, these investigators began to offer percutaneous embolization as a treatment option. They presented their initial experience with this technique. There were 27 patients with a mean age of 16 years (range of 13 to 19 years). Indications included pain (48 %), varicocele size (30 %) and persistent testicular asymmetry (22 %). Four patients had experienced failure of a previous surgical repair. Follow-up data were available for 21 patients (mean of 9 months). The varicocele resolved in 19 patients (91 %) with no evidence of hydrocele formation in any of the boys. There was resolution of pain in all patients for whom this was the indication for the procedure. In the 2 failures, access to the lower spermatic vein was not possible owing to the number and tortuosity of the vessels. The authors concluded that percutaneous embolization and sclerotherapy represent a truly minimally invasive treatment with low morbidity, minimal pain and rapid recovery. In the authors' experience, since lymphatic channels are completely avoided, there appears to be no risk of hydrocele formation.
Kondoh et al (2010) stated that surgical ligation for varicocele is primarily used in the management of male infertility patients. However, effectiveness of the ligation for painful varicocele is still controversial. These investigators reviewed records from 18 patients (average age of 17.8 years) who underwent varicocele ligation done for pain at the authors' institution from June 1999 to May 2010. The varicocele was on the left side and was grade III in 15 cases and grade II in 3 cases. The pain was classified into 3 types: (i) discomfort, (ii) dull pain, and (iii) sharp pain. Microsurgical varicocelectomy was done with inguinal or subinguinal approach. Evaluation of post-operative pain was available in 17 patients, and 15 patients (88 %) reported complete resolution of the pain with averaged follow-up duration of 11 months (3 to 53 months). The authors concluded that microsurgical varicocelectomy using the inguinal or subinguinal approach was an effective treatment modality for varicocele-associated pain.
Seo et al (2010) evaluated the improvement of seminal characteristics and pregnancy rates after microsurgical varicocelectomy in men with subclinical varicocele. A total of 143 patients with a subclinical left-sided varicocele were included in this study. Patients who agreed to microsurgical varicocelectomy (n = 25, surgery group), medical treatment with L-carnitine (n = 93 drug group), and those who did not agree to any treatment (n = 25, observation group) were enrolled. Semen characteristics were re-evaluated twice 6 months after treatment. The natural pregnancy rates were estimated by telephone interview between 1 and 2 years after treatment. In the surgery group, sperm counts improved significantly after microsurgical varicocelectomy. In the drug group, however, sperm parameters did not significantly improve after treatment. Natural pregnancy rates were 60.0 % in the surgery group, 34.5 % in the drug group, and 18.7 % in the observation group. The natural pregnancy rate of the surgery group was higher than the other groups, and there were statistically significant differences among the 3 groups. The authors concluded that surgical treatment is the best option for management of subclinical varicocele.
In a prospective, non-masked, parallel-group randomized, controlled trial, Abdel-Meguid and colleagues (2011) examined if varicocele treatment is superior or inferior to no treatment in male infertility from an evidence-based perspective. Married men 20 to 39 years of age who had experienced infertility greater than or equal to 1 year, had palpable varicoceles, and with at least 1 impaired semen parameter (e.g., sperm concentration less than 20 million/ml, progressive motility less than 50 %, or normal morphology less than 30 %) were eligible. Exclusions included subclinical or recurrent varicoceles, normal semen parameters, and azoospermia. Sample size analysis suggested 68 participants per arm. Participants were randomly allocated to observation (the control arm [CA]) or subinguinal microsurgical varicocelectomy (the treatment arm [TA]). Semen analyses were obtained at baseline (3 analyses) and at follow-up months 3, 6, 9, and 12. The mean of each sperm parameter at baseline and follow-ups was determined. These researchers measured the spontaneous pregnancy rate (the primary outcome), changes from baseline in mean semen parameters, and the occurrence of adverse events (AE-the secondary outcomes) during 12-month follow-up; p < 0.05 was considered significant. Analysis included 145 participants (CA: n = 72; TA: n = 73), with a mean age plus or minus standard deviation of 29.3 +/- 5.7 in the CA and 28.4 +/- 5.7 in the TA (p = 0.34). Baseline characteristics in both arms were comparable. Spontaneous pregnancy was achieved in 13.9 % (CA) versus 32.9 % (TA), with an odds ratio of 3.04 (95 % confidence interval [CI]: 1.33 to 6.95) and a number needed to treat of 5.27 patients (95 % CI: 1.55 to 8.99). In CA within-arm analysis, none of semen parameters revealed significant changes from baseline (sperm concentration [p = 0.18], progressive motility [p = 0.29], and normal morphology [p = 0.05]). Conversely, in TA within-arm analysis, the mean of all semen parameters improved significantly in follow-up versus baseline (p < 0.0001). In between-arm analysis, all semen parameters improved significantly in the TA versus CA (p < 0.0001). No AEs were reported. The authors concluded that these findings provided level 1b evidence of the superiority of varicocelectomy over observation in infertile men with palpable varicoceles and impaired semen quality, with increased odds of spontaneous pregnancy and improvements in semen characteristics within 1-year of follow-up.
Diegidio and colleagues (2010) reviewed all the various techniques and their results and efficiencies to provide practicing urologists with some guidance for choice of technique. These investigators discussed improvements of varicocelectomy techniques in the last 15 years and their impact on results of surgery. Pregnancy rates were highest with microsurgical subinguinal technique. Varicocele recurrence rates were lowest with microsurgical subinguinal technique. Hydrocele formation rates were lowest with microsurgical inguinal technique. Surgical complications were highest in the laparoscopic technique. Varicocelectomy by itself or in conjunction with in-vitro fertilization is cost-effective. The authors concluded that microsurgical subinguinal or microsurgical inguinal techniques offer best outcomes; and varicocelectomy is a cost- effective treatment modality for infertility.
The European Association of Urology (EAU)'s guidelines on pediatric urology (Tekgul et al, 2009) stated that for the treatment of varicocele in children and adolescents, surgical intervention is based on ligation or occlusion of the internal spermatic veins. Ligation is performed at different levels: (i) inguinal (or subinguinal) microsurgical ligation, and (ii) suprainguinal ligation, using open or laparoscopic techniques. The advantage of the former is the lower invasiveness of the procedure, while the advantage of the latter is a considerably lower number of veins to be ligated and safety of the incidental division of the internal spermatic artery at the suprainguinal level. Moreover, lymphatic-sparing varicocelectomy is preferred to prevent hydrocele formation and testicular hypertrophy development and to achieve a better testicular function according to the luteinizing hormone-releasing hormone stimulation test. The methods of choice are subinguinal or inguinal microsurgical (microscopic) repairs, or suprainguinal open or laparoscopic lymphatic-sparing repairs.
Furthermore, the EAU's guidelines on male infertility (Dohle et al, 2010) stated that several treatments are available for varicocele, and that the type of intervention chosen depends mainly on the therapist’s experience. Morevoer, an accompanying table in the EAU guideline reported a lower recurrence rate (0.8 % to 4.0 %) with microsurgical varicocelectomy than with alternative approaches (3.0 % to 29.0 %).
In a randomized study, Pourmand et al (2014) examined if addition of L-carnitine therapy to standard varicocelectomy adds any extra benefit in terms of improvement in semen parameters or deoxyribonucleic acid (DNA) damage. A total of 100 patients enrolled in this study and were randomly divided into 2 groups (50 patients in each group). In group 1, standard inguinal varicocelectomy and, in group 2, standard inguinal varicocelectomy plus oral anti-oxidant therapy (oral L-carnitine, 250 mg 3 times a day) were performed for 6 months. For all patients, routine semen analysis and DNA damage test of spermatozoa (by 2 methods of terminal deoxynucleotidyl transferase dUTP nick end labeling and protamine damage assay) were performed at baseline and at 3 and 6 months post-operatively. In both groups, the improvement in semen analysis parameters and DNA damage was observed, but there was not any statistically significant difference between the 2 groups in these parameters, although the slope of improvement in DNA damage was slightly better in group 2 (that was not statistically significant). The authors concluded that addition of 750 mg of L-carnitine orally daily to standard inguinal varicocelectomy does not add any extra benefit in terms of improvement in semen analysis parameters or DNA damage.
In a Cochrane review, Showell and colleagues (2014) evaluated the safety and effectiveness of oral supplementation with anti-oxidants for subfertile male partners in couples seeking fertility assistance. These investigators searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO and AMED databases (from inception until January 2014); trial registers; sources of unpublished literature and reference lists. An updated search was run in August 2014 when potentially eligible studies were placed in 'studies awaiting assessment'. These researchers included randomized controlled trials (RCTs) comparing any type or dose of anti-oxidant supplement (single or combined) taken by the subfertile male partner of a couple seeking fertility assistance with a placebo, no treatment or another antioxidant. Two review-authors independently selected eligible studies, extracted the data and assessed the risk of bias of the included studies. The primary review outcome was live birth; secondary outcomes included clinical pregnancy rates, adverse events, sperm DNA fragmentation, sperm motility and concentration. Data were combined, where appropriate, to calculate pooled odds ratios (ORs) or mean differences (MD) and 95 % CIs. Statistical heterogeneity was assessed using the I(2) statistic. The authors assessed the overall quality of the evidence for the main outcomes using GRADE methods. This updated review included 48 RCTs that compared single and combined antioxidants with placebo, no treatment or another anti-oxidant in a population of 4,179 subfertile men. The duration of the trials ranged from 3 to 26 weeks with follow-up ranging from 3 weeks to 2 years. The men were aged from 20 to 52 years. Most of the men enrolled in these trials had low total sperm motility and sperm concentration. One study enrolled men after varicocelectomy, 1 enrolled men with a varicocoele, and 1 recruited men with chronic prostatitis. Three trials enrolled men who, as a couple, were undergoing in-vitro fertilization (IVF) or intra-cytoplasmic sperm injection (ICSI) and 1 trial enrolled men who were part of a couple undergoing intra-uterine insemination (IUI). Funding sources were stated by 15 trials; 4 of these trials stated that funding was from a commercial source and the remaining 11 obtained funding through non-commercial avenues or university grants; 33 trials did not report any funding sources. A limitation of this review was that in a sense these researchers had included 2 different groups of trials, those that reported on the use of anti-oxidants and the effect on live birth and clinical pregnancy, and a second group that reported on sperm parameters as their primary outcome and had no intention of reporting the primary outcomes of this review. These investigators included 25 trials reporting on sperm parameters and only 3 of these reported on live birth or clinical pregnancy. Other limitations included poor reporting of study methods, imprecision, the small number of trials providing usable data, the small sample size of many of the included studies and the lack of adverse events reporting. The evidence was graded as 'very low' to 'low'. The data were current to January 31, 2014. Live birth: anti-oxidants may have increased live birth rates (OR 4.21, 95 % CI: 2.08 to 8.51, p < 0.0001, 4 RCTs, 277 men, I(2) = 0 %, low quality evidence). This suggested that if the chance of a live birth following placebo or no treatment is assumed to be 5 %, the chance following the use of anti-oxidants is estimated to be between 10 % and 31 %. However, this result was based on only 44 live births from a total of 277 couples in 4 small studies. Clinical pregnancy rate: anti-oxidants may have increased clinical pregnancy rates (OR 3.43, 95 % CI: 1.92 to 6.11, p < 0.0001, 7 RCTs, 522 men, I(2) = 0 %, low quality evidence). This suggested that if the chance of clinical pregnancy following placebo or no treatment is assumed to be 6 %, the chance following the use of anti-oxidants is estimated at between 11 % and 28 %. However, there were only 7 small studies in this analysis and the quality of the evidence was rated as low. Miscarriage: only 3 trials reported on this outcome and the event rate was very low. There was insufficient evidence to show whether there was a difference in miscarriage rates between the anti-oxidant and placebo or no treatment groups (OR 1.74, 95 % CI: 0.40 to 7.60, p = 0.46, 3 RCTs, 247 men, I(2) = 0 %, very low quality evidence). The findings suggested that in a population of subfertile men with an expected miscarriage rate of 2 %, use of an anti-oxidant would result in the risk of a miscarriage lying between 1 % and 13 %. Gastro-intestinal upsets: there was insufficient evidence to show whether there was a difference in gastro-intestinal upsets when anti-oxidants were compared to placebo or no treatment as the event rate was very low (OR 1.60, 95 % CI: 0.47 to 5.50, p = 0.46, 6 RCTs, 429 men, I(2) = 0 %). These researchers were unable to draw any conclusions from the anti-oxidant versus anti-oxidant comparison as not enough trials compared the same interventions. The authors concluded that there is low quality evidence from only 4 small RCTs suggesting that anti-oxidant supplementation in subfertile males may improve live birth rates for couples attending fertility clinics. Low quality evidence suggested that clinical pregnancy rates may increase. There is no evidence of increased risk of miscarriage but this is uncertain as the evidence is of very low quality. Data were lacking on other adverse effects. They stated that further large well-designed RCTs are needed to clarify these results.
Endoluminal Occlusion Device:
Venbrux et al (2014) determined the safety and effectiveness of a new endoluminal occlusion device, ArtVentive endoluminal occlusion system (EOS), to occlude the spermatic vein in symptomatic males with varicoceles. The ArtVentive EOS device has been developed for percutaneous, peripheral occlusion of the peripheral arterial and venous vasculature. The system is comprised of an implantable occlusion device and a delivery catheter. At present, there are 2 device sizes: (i) size 1 for target vessels ranging between 3.5 and 5.5 mm in diameter, and (ii) size 2 for target vessels 5.5 to 8.5 mm in diameter. The treatment group included 6 adult males, aged 22 to 34 years; 9 target vessels were occluded and a total of 20 devices were implanted in 6 subjects. The acute occlusion rate at the end of the procedure was 100 % occurring in 9 of 9 vessels. The spermatic veins of all patients remained occluded on venography at 30 days follow-up. Pain scores related to varicoceles decreased in 5 of 6 patients. The authors concluded that although they recognized this study was limited, initial experience indicated that the ArtVentive EOS is a safe and effective new device for occlusion of vessels (varicoceles). They stated that the device has potential applications in other clinical conditions requiring occlusion of veins or arteries.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|Other CPT codes related to the CPB:|
|35476||Transluminal balloon angioplasty, percutaneous; venous|
|37799||Unlisted procedure, vascular surgery|
|55530 - 55540||Excision of varicocele or ligation of spermatic veins for varicocele|
|HCPCS codes not covered for indications listed in the CPB:|
|ArtVentive endoluminal occlusion system - no specific cde:|
|ICD-10 codes covered if selection criteria are met:|
|N46.01 - N46.029||Azoospermia|
|N46.11 - N46.129||Oligospermia|